Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1209 Monotherapy in Primary Hypercholesterolemia and Mixed Hyperlipemia
NCT04849000Phase 3Completed
- Sponsor
- Hengrui
- Start
- Apr 2021
- Primary completion
- Jun 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypercholesterolemia and mixed hyperlipidemia comparing SHR-1209 with Placebo (2 arms). Primary endpoint: Percentage change in LDL-C relative to baseline at 16 weeks. Started Apr 2021; status: completed.
02
Drugs
recaticimab
03
Conditions
hypercholesterolemiamixed hyperlipidemia
Beyond the preview
Go deeper on NCT04849000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04849000.